keyword
MENU ▼
Read by QxMD icon Read
search

sulfonylureas

keyword
https://www.readbyqxmd.com/read/28548941/prognostic-role-of-anti-diabetic-drugs-in-pancreatic-cancer-a-systematic-review-and-meta-analysis
#1
Lei Zheng, Shinan Yin, Fenghua Yao, Hua Bai, Danqing Jing
Anti-diabetic drugs (ADDs) have been reported to modify the risk and survival of several malignancies, but whether ADDs affect the prognostic outcomes for pancreatic cancer (PC) patients remains unclear. A systematic literature search was performed for studies published until September 2016 investigating the associations between ADD use and PC survival. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using the random-effects model. Overall survival (OS) and progression-free survival (PFS) were set as the main outcomes...
May 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28548024/a-randomized-double-blind-non-inferiority-trial-evaluating-the-efficacy-and-safety-of-omarigliptin-a-once-weekly-dpp-4-inhibitor-or-glimepiride-in-patients-with-type-2-diabetes-inadequately-controlled-on-metformin-monotherapy
#2
Yehuda Handelsman, Brett Lauring, Ira Gantz, Carol Iredale, Edward A O'Neill, Ziwen Wei, Shailaja Suryawanshi, Keith D Kaufman, Samuel S Engel, Eseng Lai
OBJECTIVE: To evaluate the efficacy and safety of adding the once-weekly DPP-4 inhibitor omarigliptin or the sulfonylurea glimepiride to the treatment regimen of patients with type 2 diabetes (T2DM) and inadequate glycemic control on metformin monotherapy. METHODS: Patients with T2DM and HbA1c ≥6.5% to ≤9.0% while on a stable dose of metformin (≥1500 mg/day) were randomized to omarigliptin 25 mg once-weekly (N = 376) or glimepiride up to 6 mg once-daily (N = 375) for 54 weeks...
May 26, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28545784/pro-and-antiarrhythmic-actions-of-sulfonylureas-mechanistic-and-clinical-evidence
#3
REVIEW
Charles E Leonard, Sean Hennessy, Xu Han, David S Siscovick, James H Flory, Rajat Deo
Sulfonylureas are the most commonly used second-line drug class for treating type 2 diabetes mellitus (T2DM). While the cardiovascular safety of sulfonylureas has been examined in several trials and nonrandomized studies, little is known of their specific effects on sudden cardiac arrest (SCA) and related serious arrhythmic outcomes. This knowledge gap is striking, because persons with DM are at increased risk of SCA. In this review, we explore the influence of sulfonylureas on the risk of serious arrhythmias, with specific foci on ischemic preconditioning, cardiac excitability, and serious hypoglycemia as putative mechanisms...
May 22, 2017: Trends in Endocrinology and Metabolism: TEM
https://www.readbyqxmd.com/read/28544081/direct-medical-costs-of-severe-hypoglycaemic-events-in-patients-with-type-2-diabetes-in-england-a-retrospective-database-study
#4
Tim Holbrook, Yuexin Tang, Romita Das, R Ravi Shankar, Kaan Tunceli, Jean Williams, Larry Radican, Sarah E Holden, Chris Ll Morgan, James Piercy, Craig J Currie
AIMS: Hypoglycaemia in patients with diabetes can be induced by insulins and sulfonylureas. We assessed the real-world impact of specific monotherapy and combination regimens on hypoglycaemic events requiring hospitalisation and related secondary costs to the English healthcare system. METHODS: This retrospective observational study used the Clinical Practice Research Datalink with linked hospital admission data during 2008-2012. Patients with type 2 diabetes mellitus (T2DM) using antihyperglycaemic agents (AHAs) were assigned to mutually exclusive subgroups (insulin- and non-insulin-containing regimens; treatment groups of interest; age group) based on treatment at index date (date of first AHA prescription)...
May 23, 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28542373/comparative-effectiveness-of-oral-antidiabetic-drugs-in-preventing-cardiovascular-mortality-and-morbidity-a-network-meta-analysis
#5
Gyeongsil Lee, Seung-Won Oh, Seung-Sik Hwang, Ji Won Yoon, Sungchan Kang, Hee-Kyung Joh, Hyuktae Kwon, Jeehyun Kim, Danbee Park
In the Guidance for Industry from the Food and Drug Administration in 2008, excess cardiovascular risk should be ruled out in trials of all new antidiabetic drugs; however, relatively few studies have focused on cardiovascular safety with antidiabetic drug use. We aimed to examine mortality and cardiovascular risk using a network meta-analysis. We searched the Medline, Embase, Cochrane, and ClinicalTrials.gov registry databases in March 2016 to identify randomized controlled trials reporting cardiovascular risk with the following oral antidiabetic drugs: metformin, sulfonylureas, thiazolidinedione (TZD), dipeptidyl peptidase-4 (DPP4) inhibitors, and sodium-glucose co-transporter-2 (SGLT2) inhibitors...
2017: PloS One
https://www.readbyqxmd.com/read/28541801/enemies-or-weapons-in-hands-investigational-anti-diabetic-drug-glibenclamide-and-cancer-risk
#6
Rui Gao, Tao Yang, Wei Xu
Epidemiological evidence suggests that diabetes is associated with elevated cancer risk through the actions of hyperglycemia, hyperinsulinemia and chronic inflammation. Metformin, a first-line medication for type 2 diabetes mellitus, arouses growing concerns on its anti-cancer effect. However, data regarding the effect of glibenclamide on tumor growth and cancer risk are less consistent, which may be a potential anti-cancer drug. Areas covered: In this review, we clarified probable underlying mechanisms in preclinical studies and reviewed epidemiological evidence on glibenclamide's cancer risk in clinical studies...
May 25, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28540314/neonatal-diabetes-case-report-of-a-9-week-old-presenting-diabetic-ketoacidosis-due-to-an-activating-abcc8-gene-mutation
#7
Shawn Sood, Hannah Landreth, Jessee Bustinza, Laura Chalmers, Roopa Thukaram
Context: Neonatal diabetes mellitus, a rare condition occurring in approximately 1 in 500 000 live births, is defined as insulin-requiring hyperglycemia presenting in the first months of life. Neonatal diabetes can be transient or permanent, with studies characterizing the condition as a monogenic disorder. Case Report: We describe a case of a 9-week-old infant with neonatal diabetes who presented in diabetic ketoacidosis due to a mutation affecting the ABCC8 gene that encodes the SUR1 subunit of the potassium ATP channel...
January 2017: Journal of Investigative Medicine High Impact Case Reports
https://www.readbyqxmd.com/read/28539088/prescription-patterns-and-disease-control-in-type-2-diabetes-mellitus-patients-in-nursing-home-and-home-care-settings-a-retrospective-analysis-in-germany
#8
Karel Kostev, Timo Rockel, Louis Jacob
AIM: The aim of this study was to analyze prescription patterns and disease control in patients with type 2 diabetes mellitus (T2DM) in nursing home and home care settings in Germany. METHODS: The present study is based on data from the Disease Analyzer database (QuintilesIMS). Patients with an initial diagnosis of T2DM and documented HbA1c values between January 2011 and December 2015 were included in the analysis. The index date corresponded to the last documented HbA1c value...
May 1, 2017: Journal of Diabetes Science and Technology
https://www.readbyqxmd.com/read/28537056/comparison-of-antidiabetic-regimens-in-patients-with-type-2-diabetes-uncontrolled-by-combination-therapy-of-sulfonylurea-and-metformin-results-of-the-mohas-disease-registry-in-korea
#9
Sung Hee Choi, Tae Jung Oh, Hak Chul Jang
BACKGROUND: The aim of this study was to investigate the glucose-lowering efficacy of antidiabetic treatments in patients with type 2 diabetes mellitus (T2DM) uncontrolled by sulfonylurea plus metformin. METHODS: This open-label, multicenter, prospective, observational study was conducted in 144 centers in Korea, from June 2008 to July 2010, and included patients with T2DM who had received sulfonylurea and metformin for at least 3 months and had levels of glycosylated hemoglobin (HbA1c) >7...
May 11, 2017: Diabetes & Metabolism Journal
https://www.readbyqxmd.com/read/28533491/prognostic-significance-of-anti-diabetic-medications-in-pancreatic-cancer-a-meta-analysis
#10
Dong-Chu Zhou, Hui Gong, Chong-Qing Tan, Jian-Quan Luo
The role of anti-diabetic medications in pancreatic cancer remains conflicting. We carried out a systematic search of Pubmed and Embase databases for studies published before August 2016, which assessed the associations between anti-diabetic medications (metformin, sulfonylureas, thiazolidinediones and insulin) intake and pancreatic cancer prognosis. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using the random-effects model. The primary outcomes of interest were overall survival (OS) and progression-free survival (PFS)...
May 9, 2017: Oncotarget
https://www.readbyqxmd.com/read/28526416/treatment-strategy-for-type-2-diabetes-with-obesity-focus-on-glucagon-like-peptide-1-receptor-agonists
#11
REVIEW
Qiuhe Ji
PURPOSE: The progressive nature of type 2 diabetes mellitus (T2DM) calls for step-wise intensification of therapy for maintaining normal glycemic levels and lowering cardiovascular (CV) risk. Because obesity is a prominent risk factor and comorbidity of T2DM, it further elevates the CV risk in T2DM. Therefore, it is vital to manage weight, obesity, and glycemic parameters for effective T2DM management. Few oral antidiabetic drugs (sulfonylureas and thiazolidinediones) and insulin are not suitable for obese patients with T2DM because these drugs cause weight gain...
May 16, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28523719/cardiovascular-events-associated-with-second-line-anti-diabetes-treatments-analysis-of-real-world-korean-data
#12
K H Ha, B Kim, H Choi, D J Kim, H C Kim
AIM: To compare the risks of cardiovascular disease (CVD) and all-cause mortality associated with sulfonylurea (SU), dipeptidyl peptidase-4 inhibitor (DPP4i) and thiazolidinedione (TZD) as add-on medications to metformin (MET) therapy in people with Type 2 diabetes. METHODS: We identified 40 263 individuals who used SU (n = 11 582), DPP4i (n = 26 623) or TZD (n = 2058) in addition to MET between January 2013 and June 2015 from the database of the Korean National Health Insurance, the single-payer healthcare system in South Korea...
May 19, 2017: Diabetic Medicine: a Journal of the British Diabetic Association
https://www.readbyqxmd.com/read/28515791/vildagliptin-has-the-same-safety-profile-as-a-sulfonylurea-on-bone-metabolism-and-bone-mineral-density-in-post-menopausal-women-with-type-2-diabetes-a-randomized-controlled-trial
#13
Andre Gustavo Daher Vianna, Claudio Silva de Lacerda, Luciana Muniz Pechmann, Michelle Garcia Polesel, Emerson Cestari Marino, Victoria Zeghbi Cochenski Borba, Fellype de Carvalho Barreto
BACKGROUND: Several antidiabetic therapies affect bone metabolism. Sulfonylureas have the lowest impact on bone among oral antidiabetics. The objective of this study is to compare the effects of vildagliptin and gliclazide modified release (MR) on bone turnover markers (BTMs) and bone mineral density (BMD) in postmenopausal women with uncontrolled type 2 diabetes (T2D). METHODS: Forty-two postmenopausal women with uncontrolled T2D were randomly allocated into vildagliptin or gliclazide MR (control) groups...
2017: Diabetology & Metabolic Syndrome
https://www.readbyqxmd.com/read/28515126/radiomanganese-pet-detects-changes-in-functional-%C3%AE-cell-mass-in-mouse-models-of-diabetes
#14
Reinier Hernandez, Stephen A Graves, Trillian Gregg, Halena R VanDeusen, Rachel J Fenske, Haley N Wienkes, Christopher G England, Hector F Valdovinos, Justin J Jeffery, Todd E Barnhart, Gregory W Severin, Robert J Nickles, Michelle E Kimple, Matthew J Merrins, Weibo Cai
The noninvasive measurement of functional β-cell mass would be clinically valuable for monitoring the progression of type 1 and type 2 diabetes, as well as the viability of transplanted insulin-producing cells. Although previous work employing magnetic resonance imaging has shown promise for functional β-cell mass determination through voltage-dependent Ca(2+) channel (VDCC)-mediated internalization of Mn(2+), the clinical utility of this technique is limited by the cytotoxic levels of Mn(2+) contrast agent...
May 17, 2017: Diabetes
https://www.readbyqxmd.com/read/28514729/meglitinides-increase-the-risk-of-hypoglycemia-in-diabetic-patients-with-advanced-chronic-kidney-disease-a-nationwide-population-based-study
#15
Pei-Chen Wu, Vin-Cent Wu, Cheng-Jui Lin, Chi-Feng Pan, Chih-Yang Chen, Tao-Min Huang, Che-Hsiung Wu, Likwang Chen, Chih-Jen Wu
The safety of short-acting meglitinides in diabetic patients with advanced chronic kidney disease (CKD) has not been widely reported.Diabetic patients with advanced CKD who had a serum creatinine level of > 6 mg/dL a hematocrit level of ≦ 28% and received erythropoiesis-stimulating agent treatment between 2000 and 2010, were included in this nationwide study in Taiwan.The outcomes of interest were defined as hypoglycemia and long-term mortality. The risks of hypoglycemia and death were analyzed using Cox proportional hazards models, with end-stage renal disease and anti-diabetic drugs as time-dependent variables...
April 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28511139/a-successful-transition-to-sulfonylurea-treatment-in-male-infant-with-neonatal-diabetes-caused-by-the-novel-abcc8-gene-mutation-and-three-years-follow-up
#16
Dragan Katanic, Ivana Vorgučin, Andrew Hattersley, Sian Ellard, Jayne A L Houghton, Dragana Obreht, Marija Knežević Pogančev, Jovan Vlaški, Danijela Pavkov
Neonatal diabetes mellitus is a rare monogenic disease with incidence of 1/90,000 newborns. A case of two months aged male infant with life threatening diabetic ketoacidosis is presented with novel ABCC8 gene mutation (p.F577L), successful transition from insulin to sulfonylurea and follow-up of three years.
May 3, 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/28502212/-trends-in-antidiabetic-treatment-prescribed-for-patients-with-type-2-diabetes-in-hungary-between-2001-and-2014-results-from-the-database-analysis-of-the-national-health-insurance-fund
#17
György Jermendy, Zoltán Kiss, György Rokszin, Zsolt Abonyi-Tóth, István Wittmann, Péter Kempler
In the last couple of years, significant developments in antidiabetic treatment have influenced the pharmacological treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to analyze the changes in prescribing patterns of glucose-lowering drugs for T2DM patients in Hungary between 2001 and 2014. The number of patients with newly diagnosed T2DM decreased from 75,700 (2001) to 33,700 (2014), while prevalent T2DM cases continuously increased and plateaued in 2014 with a number of registered patients of 727,000...
May 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/28501906/medication-use-for-the-treatment-of-diabetes-in-obese-individuals
#18
REVIEW
John P H Wilding
Obesity is a major cause of type 2 diabetes and may complicate type 1 diabetes. Weight loss for obese individuals with diabetes has many health benefits, often leads to improvement in glucose control and sometimes, in type 2 diabetes, near normalisation of abnormal glucose metabolism. Weight loss is difficult to maintain and attempts to lose weight may be undermined by some diabetes treatments such as sulfonylureas, thiazolidinediones and insulin. Whilst lifestyle support should be the primary approach to aid individuals who wish to lose weight, pharmacological approaches can also be considered...
May 14, 2017: Diabetologia
https://www.readbyqxmd.com/read/28498634/older-people-with-type-2-diabetes-including-those-with-chronic-kidney-disease-or-dementia-are-commonly-overtreated-with-sulfonylurea-or-insulin-therapies
#19
C E Hambling, Samuel Seidu, M J Davies, K Khunti
AIM: To evaluate potential overtreatment with sulfonylurea and insulin therapies amongst older people with Type 2 diabetes, including those with chronic kidney disease or dementia. METHODS: Using the ECLIPSE Live software tool, we developed a search to examine data on older people (age ≥ 70 years) with Type 2 diabetes, who were prescribed sulfonylurea or insulin therapies over the previous 90 days. Sixteen Norfolk general practices participated, representing a population of 24 661 older people, including 3862 (15...
May 12, 2017: Diabetic Medicine: a Journal of the British Diabetic Association
https://www.readbyqxmd.com/read/28497592/hypoglycaemia-seriousness-and-weight-gain-as-determinants-of-cardiovascular-disease-outcomes-among-sulfonylurea-users
#20
Anthony P Nunes, Kristy Iglay, Larry Radican, Samuel S Engel, Jing Yang, Michael C Doherty, David D Dore
AIMS: Certain treatments for type 2 diabetes mellitus cause hypoglycaemia and weight gain, and thus might counteract the benefits of intensive glucose control. We quantify the association of cardiovascular disease (CVD) outcomes with hypoglycaemia and weight gain among patients with type 2 diabetes treated with sulfonylureas. MATERIALS AND METHODS: This cohort study included patients from January 2009 through December 2014 identified within a deidentified nationwide electronic health records repository, including multiple provider networks and electronic medical records systems...
May 12, 2017: Diabetes, Obesity & Metabolism
keyword
keyword
109494
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"